Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.45 |
| ▸ | ITGAL | P20701 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14454108 | 0.88 | GAA (0.53) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL30786267 | 0.86 | GAA (0.52) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL14968580 | 0.86 | GAA (0.63) | GAAKMT2AJAK2JAK1TYK2 | |
| SCHEMBL1202579 | 0.86 | GAA (0.52) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL2223457 | 0.86 | GAA (0.52) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL22520853 | 0.86 | GAA (0.52) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL19524960 | 0.86 | GAA (0.52) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL14731237 | 0.85 | GAA (0.50) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL10572106 | 0.84 | PPIA (0.54) | GAACES2CES1MEN1KMT2A | |
| SCHEMBL14726034 | 0.83 | GAA (0.49) | GAACES2CES1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | claimed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | claimed |
| EP-4612134-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024095005-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-1937629-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007046513-A2 | BENZOYLUREA COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006255-A2 | HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | GAA 1103/4885CES2 1754/4885CES1 2128/4885 |
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORC, RORB, RORA | GAA 2944/4885CES2 3783/4885CES1 2270/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | GAA 2141/4885CES2 1771/4885CES1 810/4885 |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORA, RORB | GAA 2096/4885CES2 4021/4885CES1 997/4885 |
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | BTK, BRIX1, NFXL1 | GAA 1926/4885CES2 516/4885CES1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.